计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G287801-1mg |
1mg |
现货 ![]() |
| |
| G287801-5mg |
5mg |
现货 ![]() |
| |
| G287801-10mg |
10mg |
现货 ![]() |
|
| 别名 | 基于吉非替尼的PROTAC 3 | (2S,4R)-1-((S)-2-(3-(2-((5-((4-((3-氯-4-氟苯基)氨基)-7-甲氧基喹唑啉-6-基)氧)戊基)氧)乙氧基)丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-羧酰胺 |
|---|---|
| 英文别名 | Gefitinib-based Proteolysis-targeting Chimera 3 | Iressa-based PROTAC 3 | (2S,4R)-1-((S)-2-(3-(2-((5-((4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)oxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-y |
| 规格或纯度 | Moligand™, ≥98%(HPLC) |
| 英文名称 | Gefitinib-based PROTAC 3 |
| 生化机理 | 强大的EGFR降解剂。包含通过接头与VHL配体缀合的EGFR抑制剂吉非替尼(Iressa)。诱导EGFR降解(在HCC827(第19外显子)和H3255(L858R突变)细胞中,DC50分别为11.7 nM和22.3 nM)。浓度高达10μM时,野生型EGFR不会降解。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Product Introduction Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively. |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504773200 |
|---|---|
| 分子类型 | 未知 |
| IUPAC Name | (2S,4R)-1-[(2S)-2-[3-[2-[5-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypentoxy]ethoxy]propanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide |
| INCHI | InChI=1S/C47H57ClFN7O8S/c1-29-42(65-28-53-29)31-11-9-30(10-12-31)25-50-45(59)38-22-33(57)26-56(38)46(60)43(47(2,3)4)55-41(58)15-18-63-20-19-62-16-7-6-8-17-64-40-23-34-37(24-39(40)61-5)51-27-52-44(34)54-32-13-14-36(49)35(48)21-32/h9-14,21,23-24,27-28,33,38,43,57H,6-8,15-20,22,25-26H2,1-5H3,(H,50,59)(H,55,58)(H,51,52,54)/t33-,38+,43-/m1/s1 |
| InChi Key | NICKHWYZMNLEPJ-TZSMONEZSA-N |
| Canonical SMILES | CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)C3CC(CN3C(=O)C(C(C)(C)C)NC(=O)CCOCCOCCCCCOC4=C(C=C5C(=C4)C(=NC=N5)NC6=CC(=C(C=C6)F)Cl)OC)O |
| Isomeric SMILES | CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCOCCOCCCCCOC4=C(C=C5C(=C4)C(=NC=N5)NC6=CC(=C(C=C6)F)Cl)OC)O |
| PubChem CID | 135156947 |
| 分子量 | 934.52 |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL):100, 最高浓度(mM): 107.01;溶于Ethanol, 最高浓度 (mg/mL):100, 最高浓度(mM): 107.01;不溶于水 参考Cayman添加溶解性:DMF: 25 mg/ml;DMF:PBS (pH 7.2) (1:3): 0.25 mg/ml |
|---|---|
| 分子量 | 934.500 g/mol |
| XLogP3 | 6.900 |
| 氢键供体数Hydrogen Bond Donor Count | 4 |
| 氢键受体数Hydrogen Bond Acceptor Count | 14 |
| 可旋转键计数Rotatable Bond Count | 23 |
| 精确质量Exact Mass | 933.366 Da |
| 单同位素质量Monoisotopic Mass | 933.366 Da |
| 拓扑极表面积Topological Polar Surface Area | 215.000 Ų |
| 重原子数Heavy Atom Count | 65 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1480.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 3 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Appearance(G287801) | White Solid |
|---|---|
| Purity(HPLC) | 98-100(%) |
| Proton NMR spectrum | Conforms to structure |
| 1. Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, Toure M, Dong H, Qian Y, Wang J et al.. (2018) The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.. Cell Chem Biol, 25 (1): (67-77.e3). [PMID:29129716] |